BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 33547838)

  • 1. JNK pathway-associated phosphatase associates with rheumatoid arthritis risk, disease activity, and its longitudinal elevation relates to etanercept treatment response.
    Sun L; Tu J; Chen X; Dai M; Xia X; Liu C; Zhou Y
    J Clin Lab Anal; 2021 Apr; 35(4):e23709. PubMed ID: 33547838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JKAP correlates with lower disease risk and inflammation, and its increment during etanercept treatment associates with commendable treatment efficiency in rheumatoid arthritis patients.
    Mou XY; Jin D; Zhang Q; Guan JT; Jin Y
    Eur Rev Med Pharmacol Sci; 2021 Mar; 25(6):2654-2661. PubMed ID: 33829452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal monitor of Jun N-terminal kinase pathway associated phosphatase reflects clinical efficacy to triple conventional disease-modifying anti-rheumatic drugs treatment in rheumatoid arthritis patients.
    Song D; Zhu X; Wang F; Sun J
    Inflammopharmacology; 2021 Aug; 29(4):1131-1138. PubMed ID: 34254203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JNK Pathway-Associated Phosphatase as a Serum Marker for Disease Activity and Treatment Outcome of Juvenile Idiopathic Arthritis.
    Zhu S; Lv H; Luo Y; Huang Q; Shen J
    Tohoku J Exp Med; 2021 Jan; 253(1):19-28. PubMed ID: 33441511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of Ultrasound Synovitis Joint Count with Disease Activity and Its Longitudinal Variation with Treatment Response to Etanercept in Rheumatoid Arthritis.
    Wang C; Qin Y; Xu J; Li G; Lei J; Zhang C; Deng H
    Ultrasound Med Biol; 2021 Sep; 47(9):2543-2549. PubMed ID: 34175145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downregulation of JKAP is correlated with elevated disease risk, advanced disease severity, higher inflammation, and poor survival in sepsis.
    Zhao M; Huang X
    J Clin Lab Anal; 2019 Sep; 33(7):e22945. PubMed ID: 31206807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum CDC42 is increased during tumor necrosis factor inhibitor treatment, and its elevation correlates with satisfactory treatment response in rheumatoid arthritis patients.
    Yang Y; Wu B; Tian P; Huang L
    Int J Rheum Dis; 2023 Aug; 26(8):1521-1528. PubMed ID: 37382403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating JNK pathway-associated phosphatase level correlates with decreased risk, activity, inflammation level and reduced clinical response to tumor necrosis factor-α inhibitor in Crohn disease patients.
    Shi X; Yang W; Wang N; Zhu J
    Medicine (Baltimore); 2019 Aug; 98(33):e16622. PubMed ID: 31415355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mucosa-associated lymphoid tissue lymphoma translocation protein 1 in rheumatoid arthritis: Longitudinal change after treatment and correlation with treatment efficacy of tumor necrosis factor inhibitors.
    Wang F; Liu G; Xiang L; Yuan J; Tao Y; Zhang L; Zhang A; Chang X
    J Clin Lab Anal; 2022 Jun; 36(6):e24449. PubMed ID: 35500150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurement of synovium and serum dual specificity phosphatase 22 level: Their inter-correlation and potency as biomarkers in rheumatoid arthritis.
    Qian C; Chen J; Xu X; Liu Q; Gu M; Lu S; Bai H; Wang Q; Xue M
    J Clin Lab Anal; 2022 Jan; 36(1):e24111. PubMed ID: 34811816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-1β, IL-17A, CRP and biologics history might serve as potential markers for clinical response to etanercept in rheumatoid arthritis patients.
    Zhang B; Jiang W
    Inflammopharmacology; 2019 Dec; 27(6):1123-1130. PubMed ID: 31463666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JNK pathway-associated phosphatase dephosphorylates focal adhesion kinase and suppresses cell migration.
    Li JP; Fu YN; Chen YR; Tan TH
    J Biol Chem; 2010 Feb; 285(8):5472-8. PubMed ID: 20018849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum HDAC4 level in rheumatoid arthritis: Longitudinal change during treatment and correlation with clinical outcomes.
    Mou X; Jin Y; Jin D; Guan J; Zhang Q
    J Clin Lab Anal; 2022 Aug; 36(8):e24594. PubMed ID: 35792020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Niclosamide as an adjuvant to etanercept in treatment patients with active rheumatoid arthritis: an 8-week randomized controlled pilot study.
    Al-Gareeb AIA; Gorial FI; Mahmood AS
    Clin Rheumatol; 2018 Oct; 37(10):2633-2641. PubMed ID: 29882203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JKAP relates to disease risk, severity, and Th1 and Th17 differentiation in Parkinson's disease.
    Yang Q; Zhuang J; Cai P; Li L; Wang R; Chen Z
    Ann Clin Transl Neurol; 2021 Sep; 8(9):1786-1795. PubMed ID: 34289265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The implication of long non-coding RNA expression profile in rheumatoid arthritis: Correlation with treatment response to tumor necrosis factor inhibitor.
    Wang Q; Huang X; Shao Y; Liu Q; Shen J; Xia J; Zhang Z; Wang C
    Mod Rheumatol; 2023 Jan; 33(1):111-121. PubMed ID: 35141748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual specificity phosphatase 22 relates to skin lesion degree and biologics history, while its longitudinal elevation during treatment reflects better outcome in psoriasis patients.
    E C; Fang Y; Wu S; Meng Z; Qin G; Yang J
    J Clin Lab Anal; 2022 Feb; 36(2):e24199. PubMed ID: 34973040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Satisfaction with Subcutaneous Golimumab and its Auto-Injector among Rheumatoid Arthritis Patients with Inadequate Response to Adalimumab or Etanercept.
    Dehoratius RJ; Brent LH; Curtis JR; Ellis LA; Tang KL
    Patient; 2018 Jun; 11(3):361-369. PubMed ID: 29427176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial.
    Smolen JS; Szumski A; Koenig AS; Jones TV; Marshall L
    Arthritis Res Ther; 2018 Jan; 20(1):8. PubMed ID: 29338762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial.
    Moreland LW; O'Dell JR; Paulus HE; Curtis JR; Bathon JM; St Clair EW; Bridges SL; Zhang J; McVie T; Howard G; van der Heijde D; Cofield SS;
    Arthritis Rheum; 2012 Sep; 64(9):2824-35. PubMed ID: 22508468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.